JP2010503610A - 骨産生におけるカテプシンｋアンタゴニストの使用 - Google Patents

骨産生におけるカテプシンｋアンタゴニストの使用 Download PDF

Info

Publication number
JP2010503610A
JP2010503610A JP2009512230A JP2009512230A JP2010503610A JP 2010503610 A JP2010503610 A JP 2010503610A JP 2009512230 A JP2009512230 A JP 2009512230A JP 2009512230 A JP2009512230 A JP 2009512230A JP 2010503610 A JP2010503610 A JP 2010503610A
Authority
JP
Japan
Prior art keywords
bone
cathepsin
inhibitor
cells
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009512230A
Other languages
English (en)
Japanese (ja)
Inventor
ミカエル ロング
Original Assignee
ベルキュラ セラピューティクス インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベルキュラ セラピューティクス インコーポレイティッド filed Critical ベルキュラ セラピューティクス インコーポレイティッド
Publication of JP2010503610A publication Critical patent/JP2010503610A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22038—Cathepsin K (3.4.22.38)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
JP2009512230A 2006-05-22 2007-05-18 骨産生におけるカテプシンｋアンタゴニストの使用 Pending JP2010503610A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74788606P 2006-05-22 2006-05-22
US81045606P 2006-06-01 2006-06-01
PCT/US2007/069211 WO2007137149A2 (fr) 2006-05-22 2007-05-18 Utilisation d'antagonistes de la cathepsine k dans la production osseuse

Publications (1)

Publication Number Publication Date
JP2010503610A true JP2010503610A (ja) 2010-02-04

Family

ID=38724028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009512230A Pending JP2010503610A (ja) 2006-05-22 2007-05-18 骨産生におけるカテプシンｋアンタゴニストの使用

Country Status (5)

Country Link
EP (1) EP2019688A2 (fr)
JP (1) JP2010503610A (fr)
AU (1) AU2007253796A1 (fr)
CA (1) CA2652600A1 (fr)
WO (1) WO2007137149A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014152175A (ja) * 2013-02-05 2014-08-25 Jilinsheng Jinziyuan Biotechnology Ltd カテプシンｋ抑制剤としてミリセチンの用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120315697A1 (en) * 2009-02-20 2012-12-13 Ventria Bioscience Cell Culture Media Containing Combinations of Proteins
JP2012148978A (ja) * 2009-09-24 2012-08-09 Nippon Chemiphar Co Ltd 歯周病又は根尖性歯周炎の予防又は治療剤
US20130157356A1 (en) * 2010-01-25 2013-06-20 Ventria Bioscience Methods & compositions for improving protein production

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030354A1 (fr) * 1995-03-31 1996-10-03 Nippon Chemiphar Co., Ltd. Derives d'acide epoxysuccinique
JPH10512300A (ja) * 1995-10-30 1998-11-24 スミスクライン・ビーチャム・コーポレイション カテプシンｋの阻害法
WO1999011640A1 (fr) * 1997-09-04 1999-03-11 Nippon Chemiphar Co., Ltd. Derives d'epoxysuccinamide
JP2003519425A (ja) * 1999-12-30 2003-06-17 スカニア シーブイ アクチボラグ（パブル） 自動車のための警報システム
JP2003522764A (ja) * 2000-02-10 2003-07-29 ノバルティス アクチエンゲゼルシャフト ジペプチドニトリルカテプシンｋ阻害剤
JP2005504040A (ja) * 2001-08-03 2005-02-10 スミスクライン ビーチャム コーポレーション カテプシンＫ阻害剤としてのα−ケトアミド誘導体
JP2005505550A (ja) * 2001-08-30 2005-02-24 ノバルティス アクチエンゲゼルシャフト 炎症および他の疾患を処置するための、２−シアノ−４−アミノ−ピリミジン構造およびカテプシンｋ阻害活性を有するシステインプロテアーゼインヒビター
US20050054819A1 (en) * 2002-01-17 2005-03-10 Catalano John George Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
JP2005532290A (ja) * 2002-04-10 2005-10-27 スミスクライン ビーチャム コーポレーション 骨喪失を治療するためのカテプシンｋ阻害剤としての１−（オキソアミノアセチル）ペンチルカルバマート誘導体

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030354A1 (fr) * 1995-03-31 1996-10-03 Nippon Chemiphar Co., Ltd. Derives d'acide epoxysuccinique
JPH10512300A (ja) * 1995-10-30 1998-11-24 スミスクライン・ビーチャム・コーポレイション カテプシンｋの阻害法
WO1999011640A1 (fr) * 1997-09-04 1999-03-11 Nippon Chemiphar Co., Ltd. Derives d'epoxysuccinamide
JP2003519425A (ja) * 1999-12-30 2003-06-17 スカニア シーブイ アクチボラグ（パブル） 自動車のための警報システム
JP2003522764A (ja) * 2000-02-10 2003-07-29 ノバルティス アクチエンゲゼルシャフト ジペプチドニトリルカテプシンｋ阻害剤
JP2005504040A (ja) * 2001-08-03 2005-02-10 スミスクライン ビーチャム コーポレーション カテプシンＫ阻害剤としてのα−ケトアミド誘導体
JP2005505550A (ja) * 2001-08-30 2005-02-24 ノバルティス アクチエンゲゼルシャフト 炎症および他の疾患を処置するための、２−シアノ−４−アミノ−ピリミジン構造およびカテプシンｋ阻害活性を有するシステインプロテアーゼインヒビター
US20060074092A1 (en) * 2001-08-30 2006-04-06 Eva Altmann Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases
US20050054819A1 (en) * 2002-01-17 2005-03-10 Catalano John George Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
JP2005532290A (ja) * 2002-04-10 2005-10-27 スミスクライン ビーチャム コーポレーション 骨喪失を治療するためのカテプシンｋ阻害剤としての１−（オキソアミノアセチル）ペンチルカルバマート誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014152175A (ja) * 2013-02-05 2014-08-25 Jilinsheng Jinziyuan Biotechnology Ltd カテプシンｋ抑制剤としてミリセチンの用途

Also Published As

Publication number Publication date
AU2007253796A1 (en) 2007-11-29
WO2007137149A2 (fr) 2007-11-29
CA2652600A1 (fr) 2007-11-29
EP2019688A2 (fr) 2009-02-04
WO2007137149A3 (fr) 2008-02-14

Similar Documents

Publication Publication Date Title
Li et al. Exosomes from adipose-derived stem cells regulate M1/M2 macrophage phenotypic polarization to promote bone healing via miR-451a/MIF
RU2718590C2 (ru) Индукция остеогенеза путем внедрения рнк, кодирующей костный морфогенетический белок (кмб)
Zhang et al. Interleukin‐4‐loaded hydrogel scaffold regulates macrophages polarization to promote bone mesenchymal stem cells osteogenic differentiation via TGF‐β1/Smad pathway for repair of bone defect
CN109415731A (zh) 呈递用于特异性敲低白介素17受体mRNA的反义寡核苷酸(ASO)的脂质体球形核酸(SNA)构建体
NZ555294A (en) Methods and amphiphilic compositions for treating damaged nerve cells
TW201117841A (en) Pharmaceutical composition for improving myocardial infarction
CN102686720B (zh) 由牙髓细胞向成牙本质细胞的分化诱导方法
JP2008521796A (ja) コポリマー１と組み合わせた、神経発生の誘発及び幹細胞治療
CN103347497A (zh) 用于预防和治疗骨质疏松症和其它骨疾病的食品补充剂和可注射材料
Sun et al. Dual biosignal‐functional injectable microspheres for remodeling osteogenic microenvironment
US20180169136A1 (en) Use of pharmaceutical composition in preparation of drug for promoting chondrocyte generation
JP2010503610A (ja) 骨産生におけるカテプシンｋアンタゴニストの使用
CN111467364A (zh) 一种预防药物性颌骨坏死的药物
CN106535880A (zh) 促进骨形成的组合物和方法
Xia et al. Matrigel scaffold combined with Ad-hBMP7-transfected chondrocytes improves the repair of rabbit cartilage defect
Yin et al. Cell‐Based Therapies for Degenerative Musculoskeletal Diseases
US20220096600A1 (en) Periosteal skeletal stem cells in bone repair
Zhang et al. CXCL chemokines-mediated communication between macrophages and BMSCs on titanium surface promotes osteogenesis via the actin cytoskeleton pathway
AU2003218463A1 (en) Bone generation by gene therapy
US20100104641A1 (en) Therapeutic composition, and use of a cell-free substance
JP5885206B2 (ja) グリコーゲンを含有する骨形成促進剤
US8961999B2 (en) Methods and compositions for bone formation
WO2009076490A1 (fr) Utilisation d'antagonistes de la cathepsine l dans le traitement de maladie des os
US20230010110A1 (en) Histatin-1 formulation for the treatment, repair or regeneration of bone tissue in a subject
CN111818929A (zh) 用于治疗和/或预防牙周疾病的化合物、组合物和方法

Legal Events

Date Code Title Description
A625 Written request for application examination (by other person)

Free format text: JAPANESE INTERMEDIATE CODE: A625

Effective date: 20100518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130403